Compare Novavax Inc (NVAX) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Palantir Technologies Inc — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Palantir Technologies Inc trades at $208.25 (market cap $477.68B). The key difference: Palantir Technologies Inc is far larger — about 262.5× Novavax Inc's market cap, and Palantir Technologies Inc is more actively traded (41,744,992 versus 6,198,505). Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Palantir Technologies Inc for 78 Days on average.
| NVAX | PLTR | |
|---|---|---|
Market Cap | $1.82B | $477.68B |
Volume | 6,198,505 | 41,744,992 |
Sector | Health | Technology |
52-Week High | $12.56 | $207.18 |
52-Week Low | $6.22 | $107.27 |
Typical Hold Time | 59 Days | 78 Days |
Enterprise Value | $1.39B | $468.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Palantir (PLTR) trades at $209.05, up 7.74% with strong bullish momentum as it approaches resistance at $209. The stock shows exceptional fundamental performance with 56.2% revenue growth in 2025, net income margin expanding to 36.3%, and consistent earnings beats. Recent partnership with Armada for sovereign AI infrastructure and positive analyst coverage support the upward trend, though valuation metrics remain elevated with P/E of 169.9 and P/S of 83.02.
Outlook remains positive given accelerating AI adoption and strong commercial growth (149% YoY US commercial revenue). Key risks include premium valuation sensitivity and competitive AI market pressures. Analyst consensus at $191.69 suggests potential near-term consolidation, but continued execution could justify higher multiples. Cash flow trends show strong operational performance despite significant investing outlays.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
